Androgen-dependence of prostate cancer
It is now well known that PCa cells, normal or malignant, have an obligatory requirement of androgens for their growth and proliferation via activation of androgen receptors (AR) and withdrawal of androgens by ADT leads to PCa regression [6] [7] .
To-date, ADT remains the mainstay for treating
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for PCa with their mechanisms of action. Blockade of enzyme CYP17 in adrenal steroid biosynthetic pathway, reduction in adrenal androgen production Table 1 . ADT modalities and their mechanisms of action
ADT Modality Mechanism of Action

Surgical orchiectomy
Surgical orchiectomy (bilateral removal of testes) was one of the first methods used as ADT [3] , resulting in a rapid decline in serum testosterone to castrate levels (< 50 ng/dL or 1.7 nmol/L) as the testes are the principal source of circulating androgens (producing nearly 95% of total) [9] [10] . Despite being a cost-effective means, surgical orchiectomy is rarely performed these days particularly in the western world owing to the psychological trauma associated with it [11] [12] .
Diethylstilbestrol
Diethylstilbestrol (DES), a synthetic oral oestrogen, was the first pharmacological agent used for treating metastatic PCa. Estrogenic hormones, by sharing the same steroid nucleus in their chemical structure as testosterone, suppress testicular production of androgens via a negative feedback loop inhibiting the hypothalamic-pituitary-gonadal (HPG) axis [13] . Despite its efficacy, DES was withdrawn from routine clinical use following results from the 'Veterans Administration Cooperative Urological Research Group' (VACURG) studies which showed high dose DES (5mg) to cause cardiovascular toxicity in a third of treated patients with 15% experiencing a serious thromboembolic event [8] [14] . However, subsequent trials showed cardiovascular mortality to be lower with low dose DES (1mg) as compared to high dose DES without any change in the beneficial oncological effects [15] . . LHRHa were shown to have a similar survival outcome to surgical orchiectomy or DES [17] . Due to their better psychological tolerability than surgical orchiectomy and improved cardiovascular safety profile than high dose DES, LHRHa gained worldwide acceptance in the 1980s and have since remained the treatment of choice for androgen sensitive advanced PCa [8] . LHRHa are typically offered for long term therapy following a diagnosis of advanced (incurable) disease either at presentation and following failure of radical therapy with curative intent [18] . LHRHa are now also given for short term as adjuvant or neo-adjuvant to RT for localized disease after they were shown to improve clinical and survival outcomes [19] . LHRHa not only suppress serum concentration of testosterone to <5% of normal (castrate levels) but also result in an acute decline in estrogen levels to <20% of normal (aromatisation of testosterone yields estrogen in males)
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[13] [20] . As a consequence of diminished sex hormones, long term ADT with LHRHa has been associated with serious complications such as sarcopenia, anemia, sexual dysfunction and osteoporosis [21] . Intermittent ADT with LHRHa has been considered to overcome such toxicity. This involves cycling ADT with off-treatment periods, allowing testosterone to recover above castrate levels during the treatment cessation phase. Survival outcomes similar to continuous ADT have been shown with intermittent ADT in metastatic PCa [22] and potential benefits relating to body composition changes have been suggested [23] .
However current evidence appears inadequate in establishing intermittent ADT for routine clinical use [24] [25] .
Initial exposure to LHRHa leads to a 'testosterone flare reaction', due to preliminary transient activation of HPG-axis which leads to a surge in the production of testosterone. In a few patients, this can cause complications such as exacerbation of bone pain from skeletal metastasis and worsening of urinary obstructive symptoms. The flare phenomenon is blocked by administering anti-androgens a week before starting LHRHa and continuing for 2-3 weeks afterward [26] . [27] .
Anti-androgens
Anti-androgens are commonly employed for preventing the flare reaction from LHRHa therapy [26] and they have also been used in combination with LHRHa (combined androgen blockade; CAB). CAB was the first method of ADT shown to improve survival in patients with advanced disease as compared to surgical orchidectomy or DES [28] .
Suppression of testosterone synthesis in the testes does not completely eliminate serum androgens as adrenal production accounts for 5% of the circulating androgen pool [10] . Further, the potent androgen DHT is also synthesized locally in the prostate from sex hormone precursor DHEA produced in the adrenal glands. The residual androgens from a non-testicular origin stimulate PCa growth and CAB has been used to enhance the efficacy of ADT by countering this effect [10] [29]
. 
Parenteral estrogen
Oral estrogen DES was previously used as ADT but its use was curtailed owing to concerns over cardiovascular and thromboembolic toxicity [14] . Serum glucose and cholesterol profiles were also shown to be more favourable in the estradiol group than in the LHRHa group [39] . Results from a sub-study of the phase II trial evaluating bone health showed decreased lumbar spine BMD with LHRHa compared to baseline while it increased with estrogen patches [40] .
Parenteral estrogen appears to be an effective and safe therapeutic option for the treatment of PC. Future data from trials such as PATCH will contribute to the evidence-base required to establish parenteral estrogen as an alternative to contemporary ADT with LHRHa.
Treatment of castration-resistant prostate cancer
Following initial response to ADT, PCa invariably progresses to a state of resistance called castration-resistant prostate cancer (CRPC) which is associated with a poor prognosis and reduced survival.
Continued AR signalling due to intratumoral androgen synthesis, AR mutations and AR overexpression has been suggested to propel disease progression despite castrate levels of testosterone achieved with conventional ADT [8] [41] . A number of novel treatments offering survival benefit for CRPC have recently been introduced [42] [43] . These include cytotoxic chemotherapy (docetaxel, cabazitaxel) [44] , new ADT agents (abiraterone, enzalutamide) [45] [46] [47] and immunotherapy (sipuleucel-T) [48] . Low-dose oral DES (1-3 mg) has also been demonstrated to be effective and safe as a CRPC treatment with a 5-10% rate of thromboembolic events [49] [50] . Table 2 
